Alteplase (Intravenous Thrombolysis)
Treatment for Ischemic Stroke
Typical Dosage: 0.9 mg/kg IV (max 90 mg) over 60 min (10% bolus, rest infusion)
Effectiveness
85%
Safety Score
45%
Clinical Trials
108
Participants
25K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
0.9 mg/kg IV (max 90 mg) over 60 min (10% bolus, rest infusion)
Time to Effect
immediate
Treatment Duration
Single administration
Evidence Quality
HIGHNumber Needed to Treat (NNT)
9(Treat 9 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
25(Treat 25 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$1,200
Side Effect Mgmt:$0
Total Annual:$1,200
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$40,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$60,000
Cost per Remission
$60,000
Comparison vs Supportive Care Only
Cost Difference
+$21,000/year
More expensive
QALY Difference
+1.00 QALYs
Better outcomes
Dominance
No dominance
Alteplase (Intravenous Thrombolysis) Outcomes
for Ischemic Stroke
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+35%
Remission Rate
+35%
Common Side Effects
Symptomatic Intracranial Hemorrhage
+5%
Systemic bleeding (GI, GU)
+8%
Angioedema
+1%
Active Clinical Trials
8 active trials recruiting for Alteplase (Intravenous Thrombolysis) in Ischemic Stroke
a Cohort Study of Ischemic Cerebrovascular Disease
NCT05922540RECRUITING
5K participants
OBSERVATIONAL
Hunan, China
Started: Nov 1, 2022
Intravenous Thrombolysis in Acute Ischemic Stroke with Active Cancer
NCT06841965NOT YET RECRUITINGPHASE3
280 participants
INTERVENTIONAL
Started: Mar 1, 2025
Intravenous Thrombosis and Patients with Prior Ischemic Stroke Within 3 Months
NCT06841978NOT YET RECRUITINGPHASE3
306 participants
INTERVENTIONAL
Started: Mar 1, 2025
Intravenous Thrombolysis and NOAC
NCT06749834RECRUITINGPHASE3
280 participants
INTERVENTIONAL
Hangzhou, China +1 more
Started: Jan 27, 2025
Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)
NCT07119021RECRUITINGPHASE4
300 participants
INTERVENTIONAL
Beijing, China
Started: Aug 1, 2024
Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake
NCT06571149RECRUITINGPHASE4
906 participants
INTERVENTIONAL
Leuven, Belgium +13 more
Started: Mar 14, 2025
Thrombolysis in Factor Xa-inhibitors Trial
NCT06878066RECRUITINGPHASE3
300 participants
INTERVENTIONAL
Bærum, Norway +12 more
Started: Mar 14, 2025
Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants
NCT06556446RECRUITING
2.8K participants
OBSERVATIONAL
Innsbruck, Austria +32 more
Started: Jan 1, 2024
Completed Clinical Trials
7 completed trials for Alteplase (Intravenous Thrombolysis) in Ischemic Stroke
SITS-IVT in Patients >80 Years Study
NCT04260347COMPLETED
1.66K participants
OBSERVATIONAL
Stockholm, Sweden
Started: May 14, 2020
Safety of Intravenous Thrombolysis for Wake-up Stroke
NCT01183533COMPLETEDPHASE2
40 participants
INTERVENTIONAL
Birmingham, United States +2 more
Started: Jul 1, 2010
Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis
NCT02814409COMPLETEDPHASE3
1.86K participants
INTERVENTIONAL
Glasgow, United Kingdom
Started: Dec 15, 2016
Intra-arterial Versus Systemic Thrombolysis for Acute Ischemic Stroke
NCT00640367COMPLETEDPHASE3
350 participants
INTERVENTIONAL
Milan, Italy
Started: Feb 1, 2008
Tenecteplase Versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance
NCT04071613COMPLETEDPHASE2
104 participants
INTERVENTIONAL
Melbourne, Australia +4 more
Started: Jun 20, 2019
EXtending the Time Window for Thrombolysis in Posterior Circulation Stroke Without Early CT Signs
NCT05429476COMPLETEDPHASE3
234 participants
INTERVENTIONAL
Anji, China +26 more
Started: Aug 17, 2022
Acute Ischemic Stroke Interventional Study
NCT03803007COMPLETEDPHASE1, PHASE2
160 participants
INTERVENTIONAL
Bordeau, France
Started: Mar 6, 2019
Showing 20 of 110 total trials